Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2021

Feb 08, 2022

SELL
$2.61 - $4.42 $27,303 - $46,237
-10,461 Closed
0 $0
Q3 2021

Nov 12, 2021

BUY
$3.4 - $4.24 $35,567 - $44,354
10,461 New
10,461 $40,000
Q2 2021

Aug 13, 2021

SELL
$3.76 - $5.14 $68,443 - $93,563
-18,203 Closed
0 $0
Q1 2021

May 14, 2021

BUY
$4.81 - $8.74 $8,431 - $15,321
1,753 Added 10.66%
18,203 $92,000
Q4 2020

Feb 09, 2021

BUY
$5.03 - $6.31 $82,743 - $103,799
16,450 New
16,450 $87,000
Q4 2019

Feb 12, 2020

SELL
$6.48 - $8.76 $106,440 - $143,891
-16,426 Closed
0 $0
Q3 2019

Nov 12, 2019

SELL
$7.7 - $10.42 $2,825 - $3,824
-367 Reduced 2.19%
16,426 $131,000
Q2 2019

Aug 13, 2019

SELL
$8.29 - $13.22 $15,477 - $24,681
-1,867 Reduced 10.01%
16,793 $162,000
Q1 2019

May 15, 2019

BUY
$6.82 - $10.27 $1,800 - $2,711
264 Added 1.44%
18,660 $155,000
Q4 2018

Feb 14, 2019

BUY
$7.65 - $12.83 $140,729 - $236,020
18,396 New
18,396 $150,000
Q4 2017

Feb 14, 2018

SELL
$5.89 - $7.21 $129,780 - $158,865
-22,034 Closed
0 $0
Q3 2017

Nov 13, 2017

BUY
$4.43 - $6.58 $6,259 - $9,297
1,413 Added 6.85%
22,034 $140,000
Q2 2017

Aug 11, 2017

BUY
N/A
20,621
20,621 $108,000

Others Institutions Holding MNOV

About MEDICINOVA INC


  • Ticker MNOV
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 49,046,200
  • Market Cap $106M
  • Description
  • MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological disorders, such as primary and ...
More about MNOV
Track This Portfolio

Track Pro Share Advisors LLC Portfolio

Follow Pro Share Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pro Share Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Pro Share Advisors LLC with notifications on news.